Top

Gepubliceerd in:

2024 | OriginalPaper | Hoofdstuk

17. Fractuurrisico

Auteurs : Dr. R.T. de Jongh, Drs. F. Fickweiler

Uitgeverij: Bohn Stafleu van Loghum

Samenvatting

Een hoog fractuurrisico en osteoporose komen frequent voor bij patiënten die kanker doorgemaakt hebben. Het risico hierop wordt met name bepaald door de behandeling die patiënten gehad hebben, maar ook door bijkomende risicofactoren zoals laag gewicht, vitamine D-tekort en verhoogd valrisico. Na radiotherapie moet de huisarts altijd bedacht zijn op insufficiëntiefracturen. Voor de identificatie van patiënten met een hoog fractuurrisico en behandeling daarvan kunnen grotendeels de NHG-Standaard Fractuurpreventie en Richtlijn Osteoporose en fractuurpreventie gevolgd worden. Realiseer je hierbij wel dat voor de risicoinschatting de bestaande risicoscoretabellen en calculatoren meestal een onderschatting geven in deze patiëntencategorie. Voor de behandeling van een hoog fractuurrisico kunnen eveneens de bestaande richtlijnen gevolgd worden, waarbij ook aandacht voor valrisicoreductie gewenst is.

vorige hoofdstuk Ervaringsverhaal Jan

volgende hoofdstuk Neuropathie

Krul-Poel YHM, et al. Osteoporosis and increased risk of fractures. Ned Tijdschr Geneeskd. 2020;164.

Kanis JA, et al. SCOPE 2021: a new scorecard for osteoporosis in Europe. Arch Osteoporos. 2021;16(1):82.CrossRefPubMedPubMedCentral

Reuss-Borst M, et al. Prevalence of osteoporosis among cancer patients in Germany: prospective data from an oncological rehabilitation clinic. Osteoporos Int. 2012;23(4):1437–44.CrossRefPubMed

Morote J, et al. Prevalence of osteoporosis during long-term androgen deprivation therapy in patients with prostate cancer. Urology. 2007;69(3):500–4.CrossRefPubMed

Chen Z, et al. Fracture risk among breast cancer survivors: results from the Women’s health initiative observational study. Arch Intern Med. 2005;165(5):552–8.CrossRefPubMed

Kanis JA, et al. A high incidence of vertebral fracture in women with breast cancer. Br J Cancer. 1999;79(7–8):1179–81.CrossRefPubMedPubMedCentral

Shahinian VB, et al. Risk of fracture after androgen deprivation for prostate cancer. N Engl J Med. 2005;352(2):154–64.CrossRefPubMed

Schnell S, et al. The 1-year mortality of patients treated in a hip fracture program for elders. Geriatr Orthop Surg Rehabil. 2010;1(1):6–14.CrossRefPubMedPubMedCentral

Rizzoli R, et al. Cancer-associated bone disease. Osteoporos Int. 2013;24(12):2929–53.CrossRefPubMedPubMedCentral

10.

Bedatsova L, Drake MT. The skeletal impact of cancer therapies. Br J Clin Pharmacol. 2019;85(6):1161–8.CrossRefPubMedPubMedCentral

11.

Dionisio MR, et al. Clinical and translational pharmacology of drugs for the prevention and treatment of bone metastases and cancer-induced bone loss. Br J Clin Pharmacol. 2019;85(6):1114–24.CrossRefPubMedPubMedCentral

12.

Kyvernitakis I, Kostev K, Hadji P. The tamoxifen paradox-influence of adjuvant tamoxifen on fracture risk in pre- and postmenopausal women with breast cancer. Osteoporos Int. 2018;29(11):2557–64.CrossRefPubMed

13.

Gnant M, et al. Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 5-year follow-up of the ABCSG-12 bone-mineral density substudy. Lancet Oncol. 2008;9(9):840–9.CrossRefPubMed

14.

Stumpf U, et al. Influence of chemotherapy and endocrine treatment on fractures in postmenopausal women with breast cancer - a retrospective cohort study. J Bone Oncol. 2020;22:100292.CrossRefPubMedPubMedCentral

15.

Love RR, et al. Effect of tamoxifen on lumbar spine bone mineral density in postmenopausal women after 5 years. Arch Intern Med. 1994;154(22):2585–8.CrossRefPubMed

16.

Love RR, et al. Effects of tamoxifen on bone mineral density in postmenopausal women with breast cancer. N Engl J Med. 1992;326(13):852–6.CrossRefPubMed

17.

Greenspan SL, et al. Bone loss after initiation of androgen deprivation therapy in patients with prostate cancer. J Clin Endocrinol Metab. 2005;90(12):6410–7.CrossRefPubMed

18.

Taylor LG, Canfield SE, Du XL. Review of major adverse effects of androgen-deprivation therapy in men with prostate cancer. Cancer. 2009;115(11):2388–99.CrossRefPubMed

19.

Jones JM, et al. Implementing and evaluating the impact of BoneRx: a healthy bone prescription for men with prostate cancer initiating androgen deprivation therapy. J Clin Med. 2022;11(10).

20.

Cardoso F, et al. The European Society of Breast Cancer Specialists recommendations for the management of young women with breast cancer. Eur J Cancer. 2012;48(18):3355–77.CrossRefPubMed

21.

Pfeilschifter J, Diel IJ. Osteoporosis due to cancer treatment: pathogenesis and management. J Clin Oncol. 2000;18(7):1570–93.CrossRefPubMed

22.

Handforth C, et al. Cancer treatment and bone health. Calcif Tissue Int. 2018;102(2):251–64.CrossRefPubMedPubMedCentral

23.

Weilbaecher KN. Mechanisms of osteoporosis after hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2000;6(2A):165–74.CrossRefPubMed

24.

Ugurluer G, et al. Bone complications after pelvic radiation therapy: evaluation with MRI. J Med Imaging Radiat Oncol. 2014;58(3):334–40.CrossRefPubMed

25.

Oh D, Huh SJ. Insufficiency fracture after radiation therapy. Radiat Oncol J. 2014;32(4):213–20.CrossRefPubMedPubMedCentral

26.

Celii FG, Beckmann NM. Radiation-induced insufficiency fracture of the femur 18 years after radiation therapy. Radiol Case Rep. 2019;14(2):179–83.CrossRefPubMed

27.

Gado M, et al. Bad to the bone: the effects of Therapeutic Glucocorticoids on Osteoblasts and Osteocytes. Front Endocrinol (Lausanne). 2022;13:835720.CrossRefPubMed

28.

Canalis E, et al. Glucocorticoid-induced osteoporosis: pathophysiology and therapy. Osteoporos Int. 2007;18(10):1319–28.CrossRefPubMed

29.

Gupta D, et al. Prevalence of serum vitamin D deficiency and insufficiency in cancer: review of the epidemiological literature. Exp Ther Med. 2011;2(2):181–93.CrossRefPubMedPubMedCentral

30.

Gralow JR, et al. NCCN task force report: bone health in cancer care. J Natl Compr Canc Netw. 2009;7 Suppl 3:S1–32; quiz S33–5.

31.

Neuhouser ML, et al. Vitamin D insufficiency in a multiethnic cohort of breast cancer survivors. Am J Clin Nutr. 2008;88(1):133–9.CrossRefPubMed

32.

Wolf S, et al. Chemotherapy-induced peripheral neuropathy: prevention and treatment strategies. Eur J Cancer. 2008;44(11):1507–15.CrossRefPubMed

33.

Ward PR, et al. Fall-related injuries in elderly cancer patients treated with neurotoxic chemotherapy: a retrospective cohort study. J Geriatr Oncol. 2014;5(1):57–64.CrossRefPubMed

34.

Drake MT. Osteoporosis and cancer. Curr Osteoporos Rep. 2013;11(3):163–70.CrossRefPubMedPubMedCentral

35.

Myint ZW, et al. Evaluation of fall and fracture risk among men with prostate cancer treated with androgen receptor inhibitors: a systematic review and meta-analysis. JAMA Netw Open. 2020;3(11):e2025826.CrossRefPubMedPubMedCentral

36.

NHG-werkgroep, NHG-standaard fractuurpreventie. 2012.

37.

Richtlijn Osteoporose en Fractuurpreventie – https://richtlijnendatabase.nl/richtlijn/osteoporose_en_fractuurpreventie/startpagina_-_osteoporose_en_fractuurpreventie.html.

38.

Shapiro CL, et al. Management of osteoporosis in survivors of adult cancers with nonmetastatic disease: ASCO clinical practice guideline. J Clin Oncol. 2019;37(31):2916–46.CrossRefPubMed

39.

https://www.sheffield.ac.uk/FRAX/tool.aspx?country=9.

40.

Marques EA, Mota J, Carvalho J. Exercise effects on bone mineral density in older adults: a meta-analysis of randomized controlled trials. Age (Dordr). 2012;34(6):1493–515.CrossRefPubMed

41.

Cameron ID, et al. Interventions for preventing falls in older people in care facilities and hospitals. Cochrane Database Syst Rev. 2018;9:CD005465.

42.

Gillespie LD, et al. Interventions for preventing falls in older people living in the community. Cochrane Database Syst Rev. 2012(9):CD007146.

43.

Gezondheidsraad, Evaluatie van de voedingsnormen voor vitamine D. 2012: Den haag.

44.

Owen PJ, et al. Lifestyle guidelines for managing adverse effects on bone health and body composition in men treated with androgen deprivation therapy for prostate cancer: an update. Prostate Cancer Prostatic Dis. 2017;20(2):137–45.CrossRefPubMedPubMedCentral

Titel: Fractuurrisico
Auteurs: Dr. R.T. de Jongh
Drs. F. Fickweiler
Uitgeverij: Bohn Stafleu van Loghum
Boek: Klachten na kanker
Print ISBN: 978-90-368-3022-5

Elektronisch ISBN: 978-90-368-3023-2

Copyright: 2024
DOI: https://doi.org/10.1007/978-90-368-3023-2_17

Bohn Stafleu van Loghum

Deel dit onderdeel of sectie (kopieer de link)

Samenvatting

Log in om toegang te krijgen